Generali : Attractive timing to go long again
Entry price | Target | Stop-loss | Potential |
---|
€13.6 |
€15 |
€12.9 |
+10.33% |
---|
The Assicurazioni Generali S.p.A. share is coming back to a technical support zone comprising the lower bound of the trading range. This provides a good timing to go long on the stock.
Summary● The company has solid fundamentals for a short-term investment strategy.
Strengths● There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
● The stock, which is currently worth 2020 to 0.36 times its sales, is clearly overvalued in comparison with peers.
● The company's attractive earnings multiples are brought to light by a P/E ratio at 11 for the current year.
● This company will be of major interest to investors in search of a high dividend stock.
Weaknesses● The company does not generate enough profits, which is an alarming weak point.
● For the last few months, analysts have been revising downwards their earnings forecast.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.